A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.